Anti-ovarian and anti-breast cancers with dual topoisomerase II/braf600E inhibitors activities of some substituted indole derivatives.

Abd El-Galil E. Amr1,2, Mohamed M. Abdalla3*, Mohamed A. Al-Omar1, Elsayed A. Elsayed4,5

1Pharmaceutical Chemistry Department, Drug Exploration & Development Chair (DEDC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
2Applied Chemistry Department National Research Center, 12622-Dokki, Cairo, Egypt.
3Research Unit, Saco Pharm. Co., 6th October City 11632, Egypt.
4Zoology Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
5Natural and Microbial Products Department, National Research Center, 12622-Dokki, Cairo, Egypt.

Abstract

We here in report the anti-cancer and kinases inhibitor activities of some substituted indole derivatives 1-10, which were synthesized and evaluated as analgesic and anticonvulsant agents before. Ten compounds were conveniently screened for their in vitro cytotoxicity against a wide range of cell lines; these compounds showed potent activities against ovarian and breast cancer cell lines. The in vivo anti-ovarian cancer and anti-breast cancer of the most active in vitro compounds were estimated and founded highly potent. In search for the mechanism of action of anticancer activities it was found that these compounds exert their action via Topoisomerase II inhibition and inhibition of BRAF600E.

Keywords: Indole derivatives, Kinases inhibitor, Anti-cancer activities, Topoisomerase II inhibition, Inhibition of BRAF600E.

Accepted on April 12, 2016

Introduction

Indole derivatives are important class of therapeutic agents in medicinal chemistry including privileged scaffolds [1,2], anticancer [3], antioxidant [4], antirheumatoidal and anti-HIV [5,6] and also play a vital role in the immune system [7, 8]. On the other hand, indole carboxyhydrate had been used as starting materials for the synthesis of a number of indole derivatives containing pyrazoles derivatives and evaluated as potential antitumor activity [9]. Azatoxin "NSC 640737-M; 5,R,11aS-1H,6H,3-one-5,4,11,11a-tetrahydro-5-(3,5-dimethoxy-4-hydroxyphenyl)oxazolo(3',4';l,6)-pyrido[3,4-b]indole" was rationally synthesized from a model for the pharmacophore of drugs with Topoisomerase II inhibition activity [10]. Also a new series of indole, pyrimidine, and benzimidazole heterocyclic derivatives were synthesized as anticaner activities against liver cancer cell line HEPG2 [11]. In addition, some of furyl, thienyl, pyridyl, phenyl at 2- and 4-position of 5H-indeno[1,2-b]pyridine and 2-(1H-imidazol-2-yl) pyridine derivatives were evaluated for Topoisomerase I and II inhibitory activity, cytotoxicity against several human cancer cell lines [12] and BRAF kinase inhibitory activities [13]. In view of these observations and in continuation of our previous work [14-21] in heterocyclic chemistry and their pharmacological activities, herein we reported the anti-ovarian

Experimental

Chemistry

The tested compounds 1-10 were illustrated by physical and spectroscopic data which were reported by Abd El-Latif et al. [22].

Biological activities

In vitro determination of IC50 of tested compounds against different cancer cell lines

Cell lines

SKOV-3, MCF-7, HL60, HeLa, HT1080, HepG2 and SK-MEL-28 cells were supplied by American Type Culture Collection (Rockville, MD). Culture-cells were grown in RPMI-1640; all supplemented with 10% heat inactivated fetal bovine serum (FBS), 1% penicillin-streptomycin and 2 mm L-glutamine. DMEM was also supplemented with 0.01 mg/ml insulin and 1mm sodium pyruvate. Cells were grown up in a
5% CO₂ humidified incubator at 37°C and passaged bi-weekly. According to McCauley et al. [23] the cytotoxicity of the tested compounds was measured against cancer cell lines using standard MTT assay, which depends on the reduction of the soluble MTT “3-(4,5-methyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide” into a blue-purple formazan product. This reaction results from the mitochondrial reductase activity inside living cells. The results were expressed as the IC50, which induce a 50% inhibition of cell growth of treated cells when compared to the growth of control cells. Each experiment was performed at least 3 times. The standard deviations were less than 10% with confidence interval 95%.

Nude mouse studies of SK-OV-3 tumor xenografts

In vivo antiovarian cancer of the tested compounds evaluated following the adopted method [24]. The studies followed the approval of the ethical committee guidelines 50-01-05-08B (University of South Dakota, USA). Briefly, immunonegative female mice (Harlan) with 6-8 weeks old and having ~23 gm body weight were s.c. inoculated with logarithmically growing SK-OV-3 cells at the right and left flanks. After development (tumor volume reaches ~50 mm³), three animal groups of 10 animals each were formed. A s.c. implant (Innovative Research of America) loaded with 1 µm/gm of tested compounds, placebo or control were injected into the left inguinal area of the mice. Tumor growth and size were measured using a caliper measurement in two perpendicular diameters and the volume of the tumor was determined. Statistical variation in the measurements was taken into consideration.

Human breast cancer xenograft models and animal treatment

In vivo antibrast cancer of the tested compounds evaluated following the adopted method [25]. Approval protocols and guidelines from the ethical committee were strictly followed. Briefly, female athymic pathogen-free nude mice (4-6 weeks) were used to establish MCF-7 human breast cancer xenografts. The mice were s.c. injected with logarithmically growing MCF-7 cells at an appropriate concentration (total volume 0.2 ml) into the left inguinal area of the mice. Tumor growth and size were measured using a caliper measurement in two perpendicular diameters and the volume of the tumor was determined. Again, tested compounds (dissolved in PEG400:ethanol:saline (57:1: 14.3: 28.6, v/v/v), were i.p. administered at 5 and 10 mg/kg/d, 3 d/wk for 3 weeks. Control animal groups were only injected with the vehicle.

Topoisomerase II Activities

Relaxation assay

The effects of the tested compounds on Topoisomerase II were evaluated following the adopted method [26]. In brief, purified Topoisomerase II was used to relax the supercoiled pBR-322 DNA under inhibitor (test compounds) effect at assay conditions. Afterwards, electrophoresis was performed to the samples at standard conditions and the DNA was stained with ethidium bromide.

In vitro kinase assay

Protein expression and purification: The experimental method which was used in protein expression and purification has been adopted from Qin et al. [27]. The domain containing both wild and mutant human BRAF kinase was expressed in SF9 cells and purified, and then was stored -80°C until use.

In vitro ELISA-based kinase assay

The experimental method which was used in In vitro ELISA-based kinase assay has been adopted from Jie et al. [28]. The standard protocol was followed. The expressed GST MEK-His was bound to the well pre-coated with and the test compounds were added. Accordingly, the mixture was incubated at 37°C for 30 min. to start the kinase reaction, and then the reaction was stopped. Goat anti-rabbit IgG (H+L)-HRP conjugate was added followed by the substrate. The screening performed for the compound inhibition depended on high throughput protocols in 384-well plates.

IC₅₀ value determination

For IC₅₀ calculations of the related quinolol and naphthol inhibitors, the same assay described above was used at different inhibitor concentrations to generate a sigmoidal dose response curve using V₁⁶⁰⁰⁰EBRAF or W₁⁵⁰⁰⁰BRAF protein. All dose response measurements were carried out in duplicate or triplicate and IC50 values were derived from fitting the data to a sigmoidal dose response curve with a four-parameter logistic model using Graph Pad Prism [29].

Statistical analysis

IC₁₀ and IC₅₀ values were calculated using GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). Data are reported as means ± SEM and significance was calculated by Student's t-test using SPSS software (SPSS Inc., Paris, France). *p<0.05, **p<0.01, ***p<0.001.

Results and Discussion

Chemistry

Some of substituted with indole moiety, such as pyrimidine, pyridine and thiazolopyrimidine derivatives 1-10 (Figure 1) were produced in advance and evaluated as analgesic and anticonvulsant agents [22]. Herein, due to aspects of stereochemical and conformational similarity of tested compounds and some clinical used 5α-reductase inhibitors these compounds were evaluated for their 5α-reductase inhibitors activities.
Biological Activities

Anti-cancer Activities

The cytotoxicity of the tested compounds against cancer cell lines in vitro was performed with the MTT assay according to the Mosmann’s method. All the tested compounds showed potent cytotoxic activities in vitro against SKOV-3, MCF-7, HL60, HeLa, HT1080, HepG2 and SK-MEL-28 at micro molar level (Table 1). The potent activities of the tested compounds were against SKOV-3 and MCF-7, followed by HL60, HeLa, HT1080 and HepG2 cells. On the other hand, SK-MEL-28 was the least affected cell line. It can be generally concluded that the cytotoxic effect of all tested compounds was compound- and cell line-dependent. This can be explained due to the increasing in number of indole moieties in the synthesized compounds. Moreover, the dependence cytotoxic effect on the cell lien has been previously reported [30-32]. This can be explained on the differences in cell morphology and membrane structures among difference cell lines.

Table 1. In vitro cytotoxic activities of different synthesized compounds (1-10) against various cancer cell lines.

<table>
<thead>
<tr>
<th>Comp. No.</th>
<th>IC_{50} µM Tumor cell growth inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SK-OV-3</td>
</tr>
<tr>
<td>1</td>
<td>0.0091</td>
</tr>
<tr>
<td>2</td>
<td>0.0080</td>
</tr>
<tr>
<td>3</td>
<td>0.0077</td>
</tr>
<tr>
<td>4</td>
<td>0.0065</td>
</tr>
<tr>
<td>5</td>
<td>0.0054</td>
</tr>
<tr>
<td>6</td>
<td>0.0046</td>
</tr>
<tr>
<td>7</td>
<td>0.0045</td>
</tr>
<tr>
<td>8</td>
<td>0.0034</td>
</tr>
<tr>
<td>9</td>
<td>0.0032</td>
</tr>
<tr>
<td>10</td>
<td>0.0021</td>
</tr>
</tbody>
</table>

In vivo anti-ovarian cancer

The in vivo anti-ovarian cancer activities of the tested compounds against SK-OV-3 tumors were estimated and culminated on the tested compounds exerted potent anti-ovarian activities in the following descending order 10, 9, 8, 7, 6, 4, 3, 2 and 1 (Fig. 2). These compounds strongly reduced the ovarian tumor growth ratio (Vt/Vo) in comparison to the placebo. Considering the most potent compounds (10), the obtained results showed that the implanted compound reduced the tumor growth by about 53% after 5 days of implantation. The reduction percentage of the tumor growth ratio increased gradually with increasing implantation time, and consequently the compound release, where the reduction percentages recorded 70.8, 75.3, 79.4, 84.2, 86.8, 87.9 and 87.5% after 10, 15, 20, 25, 30, 35 and 40 days of implantation, respectively.

In vivo anti-breast cancer

The in vivo anti-breast cancer activities of the tested compounds were estimated and culminated on the tested compounds exerts potent anti-breast carcinoma in the same descending order 10, 9, 8, 7, 6, 4, 3, 2 and 1 (Figure 3). Where these compounds strongly decreases the breast tumor growth Vt/Vo than that of placebo. The obtained results showed that compounds 1-6 started to exert their cytotoxic effect on tumor cells only after 6 days. On the other hands compounds 7-10 showed a reduction in tumor growth after 2 days of
implantation. The most active compounds (10) resulted in a 21% reduction in tumor size growth after 2 days of implantation. Furthermore, the reduction percentage increased to reach 38.1, 73.1, 84.3, 80.1, 86.1, 82.8, 79.7, 82.6 and 80.1% after 4, 6, 8, 10, 12, 14, 16, 18 and 20 days of implantation, respectively.

**Figure 2.** Effect of different synthesized compounds (1-10) on in vivo SK-OV-3 tumor growth in nude mice.

**Mechanism of anticancer activities**

In search for the mechanism of action of the anticancer activities of the tested compounds the author's resorts to many in vitro assays for many targeted enzymes and cancer modulation molecules, these experiments revealed on the following two mechanistic pathway.

**Topoisomerase II Activities**

In search for the mechanism of action of anticancer activities of the tested compounds several proposals had been investigated and studied. Among these, the synthesized compounds were mainly active against Topoisomerase II, and showed significant inhibition for the enzyme activities. All the tested compounds inhibited the enzyme Topoisomerase II in the following descending order 10, 9, 8, 7, 6, 4, 3, 2 and 1 (Table 2). From the data presented, it can be clearly observed that Cpd. 10 inhibited the Topoisomerase II activity, and the IC50 value was 0.33 nm. Moreover, the IC50 values required to inhibit the enzyme activity increased with decreased the number of indole moieties in the synthesized compounds (order 10 to 1) by about 1.3-, 1.7, 1.9, 1.9, 2.0, 2.18, 2.24, 2.3 and 2.4-folds for Cpd. 9, 8, 7, 6, 5, 4, 3, 2 and 1, respectively.

**Table 2. IC50 of Topoisomerase II Inhibitor activities of the tested compounds 1-10.**

<table>
<thead>
<tr>
<th>Comp. No.</th>
<th>IC50 (nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.79</td>
</tr>
<tr>
<td>2</td>
<td>0.98</td>
</tr>
<tr>
<td>3</td>
<td>0.74</td>
</tr>
<tr>
<td>4</td>
<td>0.72</td>
</tr>
<tr>
<td>5</td>
<td>0.67</td>
</tr>
<tr>
<td>6</td>
<td>0.65</td>
</tr>
<tr>
<td>7</td>
<td>0.63</td>
</tr>
<tr>
<td>8</td>
<td>0.55</td>
</tr>
<tr>
<td>9</td>
<td>0.43</td>
</tr>
<tr>
<td>10</td>
<td>0.33</td>
</tr>
</tbody>
</table>

**In vitro kinase assay**

The in vitro kinase assay of the synthesized compounds was investigated against both WT-BRAF (BRAF kinase wild type) and V600E-BRAF (mutant BRAF kinase) (Table 3). All compounds were highly active inhibitors for V600E-BRAF, while showing moderate inhibiting activity against WT-BRAF. The descending order of activities was as follow 10, 9, 8, 7, 6, 4, 3, 2 and 1. Again, Cpd. 10 was the most potent and showed IC50 values of 0.0023 and 0.15 nm for V600E-BRAF and WT-BRAF, respectively. Similarly, the IC50 values obtained for the synthesized compounds increased in the same order of compound activity. The IC50 values obtained for Cp. 1, being the least effective, increased by about 5.8- and 19.3-folds for V600E-BRAF and WT-BRAF, respectively. Our results are in good agreement with those previously reported by Stones et al. [29]. The authors analyzed and compared the responses of different human melanoma cell lines to different NRAS and BRAF inhibitors and determined the corresponding IC50 values. They found that some of their investigated cell lines with BRAF mutation were sensitive to CI-1040, which is a generally applied as an inhibitor for MEK kinase. Furthermore, they
concluded that MEK inhibitors have a potential for their inhibiting effect against some human melanomas.

Table 3. IC$_{50}$ (95% confidence interval [nm]) of tested compounds 1-10 for both WT BRAF and V600E BRAF.

<table>
<thead>
<tr>
<th>Comp. No.</th>
<th>IC$_{50}$ (95% confidence interval)</th>
<th>IC$_{50}$ (95% confidence interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WT BRAF (nm)</td>
<td>V600E BRAF (nm)</td>
</tr>
<tr>
<td>1</td>
<td>0.87</td>
<td>0.0444</td>
</tr>
<tr>
<td>2</td>
<td>0.78</td>
<td>0.0151</td>
</tr>
<tr>
<td>3</td>
<td>0.65</td>
<td>0.0085</td>
</tr>
<tr>
<td>4</td>
<td>0.58</td>
<td>0.0076</td>
</tr>
<tr>
<td>5</td>
<td>0.47</td>
<td>0.0073</td>
</tr>
<tr>
<td>6</td>
<td>0.36</td>
<td>0.0065</td>
</tr>
<tr>
<td>7</td>
<td>0.33</td>
<td>0.0062</td>
</tr>
<tr>
<td>8</td>
<td>0.24</td>
<td>0.0053</td>
</tr>
<tr>
<td>9</td>
<td>0.21</td>
<td>0.0044</td>
</tr>
<tr>
<td>10</td>
<td>0.15</td>
<td>0.0023</td>
</tr>
</tbody>
</table>

Conclusion

Our obtained results showed that all synthesized compounds exhibited a significant inhibition against in vivo ovarian and breast carcinomas through the inhibition of the Topoisomerase II and BRAF600E. Careful analysis of the structure features of the synthesized compounds and their activities culminated on some SAR aspects.

Structural Activity Relationships

- Indole nucleus is essential for the potent activities and as the number of indole moities increases the activities increases.
- Pyrimidine nucleus and diazepene moities play important roles in increasing the activities but the role of pyrimidine is higher than that of diazebene.
- The effects of various moities on the activities were of the following descending order pyrimidine, diazepene, pyridine, pyran and five membered heterocyclic.

Acknowledgement

The project was financially supported by King Saud University, Vice Deanship of Research Chairs.

References


*Correspondence to:*

Mohamed M. Abdalla
Research Unit
Saco Pharm. Co
Egypt